Innovent gets seven drugs on China's 2026 NRDL, four new

SUZHOU -- November 14, 2026 -- Innovent Biologics (HKEX: 01801) had seven products included or renewed in China's updated National Reimbursement Drug List (NRDL), four of them first-time listings. The list takes effect on January 1, 2027. CEO Michael Yu says the company's NRDL-covered lineup has expanded to 17 products that have cumulatively benefited more than 20 million patients. By our calculation, the seven decisions in this round touch about 41% of that lineup (7 of 17).

Four Innovent products enter the NRDL for the first time

The new entries are mazdutide, PECONDLE (picankibart), TABOSUN (ipilimumab N01) and VANFLYTA (quizartinib). The other three were already listed. TYVYT (sintilimab) and JAYPIRCA (pirtobrutinib) gained indications, and SINTBILO (tafolecimab) was renewed.

Mazdutide is listed for adults with type 2 diabetes. The release names no other NRDL indication for it, although it cites weight-loss results from clinical studies. Innovent describes mazdutide as the first and only approved GCG/GLP-1 dual receptor agonist globally.

Picankibart is listed for adults with moderate to severe plaque psoriasis who are eligible for systemic therapy. Innovent says it is the first drug against its target to exceed an 80% PASI 90 response rate at 16 weeks in a Phase III registrational trial. The company also says it has the longest maintenance interval in its class, once every 12 weeks. Quizartinib is listed for newly diagnosed FLT3-ITD-positive acute myeloid leukemia.

Innovent did not disclose the negotiated prices behind any of the listings.

Both drugs in Innovent's colon cancer combination are now reimbursed

Ipilimumab N01 was listed for use with sintilimab as neoadjuvant treatment of resectable stage IIB-III MSI-H/dMMR colon cancer. Sintilimab's added indication is the same regimen, so both components of the combination are on the list. Innovent calls it the world's only approved dual-immunotherapy combination for this indication.

Sintilimab's second new indication is in combination with fruquintinib for locally advanced or metastatic renal cell carcinoma. It applies after failure of prior VEGFR tyrosine kinase inhibitor therapy, in patients without first-line PD-1 or PD-L1 treatment. The two additions equal 20% of the ten indications for which sintilimab is approved in China.

Pirtobrutinib's new indication covers adults with CLL/SLL who have had at least one prior systemic therapy that included a BTK inhibitor.

Partners hold development or licensing rights to four of the seven products

Eli Lilly and Company is tied to three of the seven. Innovent holds an exclusive license to mazdutide in China and co-developed sintilimab with Lilly. It also has exclusive commercialization rights to Lilly-developed pirtobrutinib in Mainland China. Daiichi Sankyo developed quizartinib, which Innovent solely commercializes in Mainland China. Innovent says it developed picankibart, ipilimumab N01 and tafolecimab independently.

Pirtobrutinib was approved in China in October 2024 and joined the NRDL on January 1, 2026, 15 months later by our calculation. Tafolecimab was approved in August 2023 and listed on January 1, 2025, 17 months later. Its renewal now runs into the 2027 list year.

Published by:
fairsonline_team
Products